30 Participants Needed

Clavulanic Acid for Quitting Smoking

BE
MA
Overseen ByMadhura Athreya, MS
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

What is the purpose of this trial?

This research study is looking into the effects of clavulanic on smoking behavior in adult cigarette smokers. The primary study hypothesis is that, compared to placebo, clavulanic acid will reduce smoking over the course of the study.

Research Team

BF

Brett Froeliger, PhD

Principal Investigator

University of Missouri-Columbia

Eligibility Criteria

This trial is for adults aged 18-65 who have been smoking more than 10 cigarettes a day for at least two years and can confirm inhalation. Participants must speak English, have functional vision, and women must test negative in a pregnancy test. They should not use other tobacco or nicotine products during the study.

Inclusion Criteria

English fluency
Smoke > 10 cigarettes/day for a minimum of 2 yrs. and have an expired carbon monoxide (CO) concentration of ≥ 10 ppm (to confirm inhalation at screening and scanning)
Functional vision (with corrective lenses as needed) to complete assigned assessments and tasks
See 2 more

Exclusion Criteria

I am taking antidepressants that help with quitting smoking.
Positive pregnancy test (Urine pregnancy testing at screening and prior to fMRI scan) or currently breast feeding or BAC greater than 0.0
I have not had electroconvulsive therapy in the last 6 months.
See 10 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

1 week

Treatment

Participants receive either clavulanic acid or placebo for 4 days, with twice-daily oral capsule administration

4 days
Daily visits for capsule administration and monitoring

Follow-up

Participants are monitored for safety and effectiveness after treatment, including fMRI and biochemical assessments

1 day
1 visit (in-person)

Treatment Details

Interventions

  • Clavulanic Acid
  • Placebo oral capsule
Trial Overview The study is testing clavulanic acid's impact on cigarette smokers' behavior by comparing it to a placebo. The main goal is to see if clavulanic acid helps reduce smoking compared to the placebo over time.
Participant Groups
2Treatment groups
Active Control
Placebo Group
Group I: ClavActive Control1 Intervention
4-day 125 bid oral capsule administration
Group II: PlaceboPlacebo Group1 Intervention
4-day, twice-daily oral capsule administration

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Missouri-Columbia

Lead Sponsor

Trials
387
Recruited
629,000+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security